Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN3 | Q9H6Z9 | 5/20 | 0.57 |
| ▸ | EGLN1 | Q9GZT9 | 12/20 | 0.46 |
| ▸ | FTO | Q9C0B1 | 6/20 | 0.46 |
| ▸ | KDM5B | Q9UGL1 | 3/20 | 0.46 |
| ▸ | KDM2A | Q9Y2K7 | 3/20 | 0.46 |
| ▸ | KDM6B | O15054 | 2/20 | 0.46 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.46 |
| ▸ | KDM3A | Q9Y4C1 | 1/20 | 0.46 |
| ▸ | ATR | Q13535 | 1/20 | 0.43 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3518710 | 0.90 | EGLN3 (0.54) | EGLN3EGLN1FTOKDM5BKDM2A | |
| SCHEMBL3519887 | 0.88 | EGLN3 (0.66) | EGLN3EGLN1FTOKDM5BKDM2A | |
| SCHEMBL3519422 | 0.88 | EGLN3 (0.53) | EGLN3EGLN1FTOKDM5BKDM2A | |
| SCHEMBL3519202 | 0.87 | EGLN3 (0.52) | EGLN3EGLN1FTOKDM5BKDM2A | |
| SCHEMBL3522327 | 0.87 | EGLN3 (0.52) | EGLN3EGLN1FTOKDM5BKDM2A | |
| SCHEMBL3520489 | 0.87 | EGLN3 (0.52) | EGLN3EGLN1FTOKDM5BKDM2A | |
| SCHEMBL3521806 | 0.87 | EGLN3 (0.52) | EGLN3EGLN1FTOKDM5BKDM2A | |
| SCHEMBL3519009 | 0.86 | EGLN3 (0.50) | EGLN3EGLN1FTOKDM5BKDM2A | |
| SCHEMBL3758723 | 0.85 | EGLN3 (0.56) | EGLN3EGLN1FTOKDM5BKDM2A | |
| SCHEMBL3761637 | 0.85 | HPGD (0.46) | EGLN3EGLN1ATR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100305133-A1 | Prolyl Hydroxylase Inhibitors | SMITHKLINE BEECHAM CORPORATION | 2010-12-02 | — | — | US | claimed |
| US-20100305133-A1 | Prolyl Hydroxylase Inhibitors | SMITHKLINE BEECHAM CORPORATION | 2010-12-02 | — | — | US | disclosed |
| US-20100305133-A1 | Prolyl Hydroxylase Inhibitors | SMITHKLINE BEECHAM CORPORATION | 2010-12-02 | — | — | US | disclosed |
| US-20100305133-A1 | Prolyl Hydroxylase Inhibitors | SMITHKLINE BEECHAM CORPORATION | 2010-12-02 | — | — | US | disclosed |
| WO-2009073497-A2 | PROLYL HYDROXYLASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-06-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100305133-A1 | Prolyl Hydroxylase Inhibitors | HIF1AN, EGLN3, EGLN2 | EGLN3 2/4885EGLN1 6/4885FTO 741/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.